In this study, we compared creatinine, cystatin C and β2-microglobulin (β2M) within the 2021 CKD-EPI eGFR framework to inform a pragmatic multi-marker approach for discriminating CKD stage 3 from stage 4. This evidence concerns the gene CST3 and chronic kidney disease.